恶性肿瘤脑转移暨乳腺癌脑转移化疗进展和分子靶向治疗-2009CSCO年会精选.pptVIP

总结 临床多学科协作将有助于改善脑转移瘤患者的预后 以替莫唑胺为代表的新型化疗药物在乳腺癌等实体瘤脑转移的治疗中表现出疗效和良好的安全性 以拉帕替尼为代表的分子靶向药物在乳腺癌脑转移的治疗中具有良好前景，值得进一步探讨 * * * * * - This phase ll study evaluated the safety and efficacy of the combination of ERBITUX and FOLFOX-4 as first-line treatment for patients with mCRC. 1. Cervantes A, Casado E, Van Cutsem E et al. Eur J Cancer 2005;Supplement 3:Abstract 642. Updated information presented at ECCO 2005 * * - In this multicenter, open-label, phase II study, patients with metastatic or recurrent CRC received first-line treatment with ERBITUX (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus FOL